| Outcome | All | CRKL | p-value‡ | CK2 β | p-value‡ | |||||||
| Low | High |
| Low | High |
| |||||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | |||
| Response to CRT | (N = 25) | (N = 5) | (N = 20) |
| (N = 4) | (N = 21) |
| |||||
| OAR | 14 | (56%) | 5 | (100%) | 9 | (45%) | 0.046 | 4 | (100%) | 10 | (47.6%) | 0.005 |
| NR | 11 | (44%) | 0 | (0%) | 11 | (55%) | 0 | (0%) | 11 | (52.4%) | ||
| Recurrence | (N = 39) | (N = 22) | (N = 17) |
| (N = 21) | (N = 18) |
| |||||
| Absent | 33 | (84.6%) | 22 | (100%) | 11 | (64.7%) | 0.004 | 20 | (95.2%) | 13 | (72.2%) | 0.048 |
| Present | 6 | (15.4%) | 0 | (0%) | 6 | (35.3%) | 1 | (4.8%) | 5 | (27.8%) | ||
| Progression | (N = 28) | (N = 6) | (N = 22) |
| (N = 5) | (N = 23) |
| |||||
| Absent | 15 | (53.6%) | 6 | (100%) | 9 | (40.9%) | 0.018 | 5 | (100%) | 10 | (43.5%) | 0.044 |
| Present | 13 | (46.4%) | 0 | (0%) | 13 | (59.1%) | 0 | (0%) | 13 | (56.5%) | ||
| Metastasis | (N = 40) | (N = 21) | (N = 19) |
| (N = 21) | (N = 19) |
| |||||
| Absent | 32 | (80%) | 19 | (90.5%) | 13 | (68.4%) | 0.020 | 19 | (90.5%) | 13 | (68.4%) | 0.030 |
| Present | 8 | (20%) | 2 | (9.5%) | 6 | (31.6%) | 2 | (9.5%) | 6 | (31.6%) | ||
| Mortality | (N = 50) | (N = 22) | (N = 28) |
| (N = 21) | (N = 29) |
| |||||
| Alive | 32 | (64%) | 20 | (90.9%) | 12 | (42.9%) | <0.001 | 19 | (90.5%) | 13 | (44.8%) | 0.001 |
| Died | 18 | (36%) | 2 | (9.1%) | 16 | (57.1%) | 2 | (9.5%) | 16 | (55.2%) | ||